Skip to content
NYSE · OPHTHALMIC GOODS · LARGE CAP

Warby Parker Inc. WRBY

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$871.9M
▲ 13.0% YoY
$1.6M
$43.7M
▲ 26.0% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Warby Parker designs its eyewear in-house at its New York City headquarters and sells it directly to customers, with pricing starting at $95 including prescription lenses. It has expanded beyond glasses to offer eye exams, contact lenses, lens enhancements, and tech-enabled tools including Virtual Try-On and Virtual Vision Test. Its contact lens assortment includes brands such as Acuvue, Biofinity, DAILIES, and Precision1. In most of its stores, it provides in-person eye exams using digital retinal imaging, with optometrists employed directly by the company or by independent professional corporations or similar entities under contractual agreements. It operates in-house optical laboratories in Sloatsburg, New York, and Las Vegas, Nevada. The company operates across digital commerce and 323 retail stores as of December 31, 2025. As of December 31, 2025, it had 4,036 employees, including 2,275 full-time and 1,761 part-time employees, across two in-house optical laboratories and two offices in the United States. In June 2021, it elected to be treated as a public benefit corporation under Delaware law.

Written from the business description in Warby Parker Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 871.9M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 871.9 · Net income 1.6
400M800M-100M-200M
201920222025
Compound annual growth
+13.4%
+17.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

0 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -0.6% · Net 0.2%
-10%-20%
201920222025
ROE
FY2025 · ROE 0.5%
-10%-20%-30%
201920222025
Three returns, three denominators.

Each USD of equity produced 0 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 43.7
20M40M-30M-60M
201920222025
Net buybacks $M Dividends $M
FY2023 · Dividends · · Net buybacks 0.0
30M60M
20192020202120222023

Total assetsUSD 720.9M
EquityUSD 367.7M
CashUSD 286.4M
Current ratio2.35×

Equity funds 51% of total assets.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
WRBY, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.90.80.70.60.50.40.4
Operating income $B−0.0−0.0−0.1−0.1−0.1−0.1−0.0
EBITDA $B0.00.0−0.0−0.1−0.1−0.00.0
Income tax $B0.00.00.00.00.00.00.0
Net income $B0.0−0.0−0.1−0.1−0.1−0.10.0
Free cash flow $B0.00.00.0−0.0−0.10.0−0.0
EPS, diluted $0.01−0.17−0.54−0.96−2.21−1.05−1.10
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %0.5−6.4−21.5−38.6———

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 33 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019. 12 checks were skipped: revenue is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityOphthalmic Goods
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2019

Share this section

Download image